未登录Inhibitors of IAP/XIAP enhance activity of sacituzumab govitecanIAP/XIAP抑制剂增强sacituzumab govitecan的活性
Ming Zhao, PhD; Bailiang Wang, MS; Kurt W Evans, MS; Stephan Scott, BS; Erkan Yuca, MS; Gabriela Raso, PhD; Yasmeen Qamar Rizvi, PhD; Xiaofeng Zheng, PhD; Dali Li, PhD; Jun Li, PhD; Han Liang, PhD; Argun Akcakanat, PhD; Michelle Brockman, PhD; Senthil Damodaran, MD, PhD; Funda Meric-Bernstam, MD .png)
分享.png)
收藏MTAP loss alters the epigenetic landscape and demonstrates superior therapeutic sensitivity to concomitant PRMT5 and PARP inhibition in cholangiocarcinomaShah, Pooja A.; Saw, Ajay Kumar; Padron, William; Zhao, Ming; Akcakanat, Argun; Evans, Kurt; Meric-Bernstam, Funda; Javle, Milind; Rodon, Jordi; Rai, Kunal 分享 收藏 Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived XenograftsDiperi, Timothy P.; Evans, Kurt W.; Wang, Bailiang; Zhao, Ming; Akcakanat, Argun; Raso, Maria Gabriela; Rizvi, Yasmeen Q.; Zheng, Xiaofeng; Korkut, Anil; Varadarajan, Kaushik; Uzunparmak, Burak; Dumbrava, Ecaterina E.; Pant, Shubham; Ajani, Jaffer A.; Pohlmann, Paula R.; Jensen, V. Behrana; Javle, Milind; Rodon, Jordi; Meric-Bernstam, Funda 分享 收藏 Co-clinical trial of novel bispecific anti-HER2 antibody Zanidatamab in Patient-Derived XenograftsDiPeri, Timothy P.; Evans, Kurt W.; Wang, Bailiang; Zhao, Ming; Akcakanat, Argun; Raso, Maria Gabriela; Rizvi, Yasmeen Q.; Zheng, Xiaofeng; Korkut, Anil; Varadarajan, Kaushik; Uzunparmak, Burak; Dumbrava, Ecaterina E.; Pant, Shubham; Ajani, Jaffer A.; Pohlmann, Paula; Jensen, V. Behrana; Javle, Milind; Rodon, Jordi; Meric-Bernstam, Funda 分享 收藏 Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer不可逆的成纤维细胞生长因子受体抑制剂futibatinib在FGFR改变的乳腺癌中的疗效Saridogan, Turcin; Akcakanat, Argun; Zhao, Ming; Evans, Kurt W.; Yuca, Erkan; Scott, Stephen; Kirby, Bryce P.; Zheng, Xiaofeng; Ha, Min Jin; Chen, Huiqin; Ng, Patrick K. S.; DiPeri, Timothy P.; Mills, Gordon B.; Ahnert, Jordi Rodon; Damodaran, Senthil; Meric-Bernstam, Funda 分享 收藏 Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan表观遗传学上调TROP2和SLFN11增强TROP2抗体药物偶联物sacitizumab govitecan的治疗效果Zhao, Ming; DiPeri, Timothy P. P.; Raso, Maria Gabriela; Zheng, Xiaofeng; Rizvi, Yasmeen Qamar; Evans, Kurt W. W.; Yang, Fei; Akcakanat, Argun; Estecio, Marco Roberto; Tripathy, Debu; Dumbrava, Ecaterina E. E.; Damodaran, Senthil; Meric-Bernstam, Funda 分享 收藏 Antitumor activity of the ATR inhibitor Elimusertib in patient-derived xenograft models with DNA damage response pathway alterationsVaradarajan, Kaushik; Pico, Christian X.; Evans, Kurt; Raso, Maria G.; Rizvi, Yasmeen; Zheng, Xiaofeng; Diperi, Timothy P.; Wang, Bailiang; Scott, Stephen; Zhao, Ming; Akcakanat, Argun; Wengner, Antje M.; Yap, Timothy A.; Meric-Bernstam, Funda 分享 收藏 Efficacy of futibatinib, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in breast cancer models with FGFR alterationsSaridogan, Turcin; Akcakanat, Argun; Zhao, Ming; Evans, Kurt W.; Yuca, Erkan; Scott, Stephen; Kirby, Bryce P.; Zheng, Xiaofeng; Damodaran, Senthil; Meric-Bernstam, Funda 分享 收藏 Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterationsPairawan, Seyed; Akcakanat, Argun; Kopetz, Scott; Tapia, Coya; Zheng, Xiaofeng; Chen, Huiqin; Ha, Min Jin; Rizvi, Yasmeen; Holla, Vijaykumar; Wang, Jing; Evans, Kurt W.; Zhao, Ming; Busaidy, Naifa; Fang, Bingliang; Roth, Jack A.; Dumbrava, Ecaterina Ileana; Meric-Bernstam, Funda 分享 收藏 Anti-tumor activity of ATR inhibitor BAY 1895344 in patient-derived xenograft (PDX) models with DNA damage response (DDR) pathway alterationsPico, Christian X. Cruz; Li, Dali; Lanier, Christopher D.; Evans, Kurt; Raso, Maria G.; DiPeri, Timothy; Rizvi, Yasmeen; Ha, Min Jin; Chen, Huiqin; Zhao, Ming; Akcakanat, Argun; Zheng, Xiaofeng; Toruner, Gokce; Yuca, Erkan; Scott, Stephen; Wengner, Antje M.; Yap, Timothy A.; Meric-Bernstam, Funda 分享 收藏 Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast CancerEvans, Kurt W.; Yuca, Erkan; Scott, Stephen S.; Zhao, Ming; Arango, Natalia Paez; Pico, Christian X. Cruz; Saridogan, Turcin; Shariati, Maryam; Class, Caleb A.; Bristow, Christopher A.; Vellano, Christopher P.; Zheng, Xiaofeng; Gonzalez-Angulo, Ana Maria; Su, Xiaoping; Tapia, Coya; Chen, Ken; Akcakanat, Argun; Lim, Bora; Tripathy, Debu; Yap, Timothy A.; Di Francesco, Maria Emilia; Draetta, Giulio F.; Jones, Philip; Heffernan, Timothy P.; Marszalek, Joseph R.; Meric-Bernstam, Funda 分享 收藏 Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast CancerAkcakanat, Argun; Zheng, Xiaofeng; Pico, Christian X. Cruz; Kim, Tae-Beom; Chen, Ken; Korkut, Anil; Sahin, Aysegul; Holla, Vijaykumar; Tarco, Emily; Singh, Gopal; Damodaran, Senthil; Mills, Gordon B.; Gonzalez-Angulo, Ana Maria; Meric-Bernstam, Funda 分享 收藏 First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models一流的双重MDM2/MDMX抑制剂ALRN-6924增强了TP53野生型激素受体阳性乳腺癌模型中化疗的抗肿瘤效果Pairawan, Seyed; Zhao, Ming; Yuca, Erkan; Annis, Allen; Evans, Kurt; Sutton, David; Carvajal, Luis; Ren, Jian-Guo; Santiago, Solimar; Guerlavais, Vincent; Akcakanat, Argun; Tapia, Coya; Yang, Fei; Bose, Priya Subash Chandra; Zheng, Xiaofeng; Dumbrava, Ecaterina Ileana; Aivado, Manuel; Meric-Bernstam, Funda 分享 收藏 Overcoming PARP inhibitor resistance with molecularly guided rational combinations in triple-negative breast cancer patient-derived xenograft modelsPico, Christian X. Cruz; Evans, Kurt W.; Chen, Ken; Zheng, Xiaofeng; Akcakanat, Argun; Zhao, Ming; Tapia, Coya; Scott, Stephen M.; Yuca, Erkan; Meric-Bernstam, Funda 分享 收藏 Oxidative phosphorylation is a metabolic vulnerability in chemotherapy resistant triple negative breast cancerEvans, Kurt; Moulder, Stacy; Yuca, Erkan; Scott, Stephen; Arango, Natalia Paez; Shariati, Maryam; Vellano, Christopher P.; Saridogan, Turcin; Zheng, Xiaofeng; Gonzalez-Angulo, Ana Maria; Zhao, Ming; Su, Xiaoping; Tapia, Coya; Chen, Ken; Akcakanat, Argun; Perou, Charles M.; Lim, Bora; Tripathy, Debu; Yap, Timothy A.; Di Francesco, Maria E.; Draetta, Giulio; Jones, Philip; Marszalek, Joe; Meric-Bernstam, Funda 分享 收藏 分享 收藏 Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutationXing, Yan; Lin, Nancy U.; Maurer, Matthew A.; Chen, Huiqin; Mahvash, Armeen; Sahin, Aysegul; Akcakanat, Argun; Li, Yisheng; Abramson, Vandana; Litton, Jennifer; Chavez-MacGregor, Mariana; Valero, Vicente; Piha-Paul, Sarina A.; Hong, David; Do, Kim-Anh; Tarco, Emily; Riall, Dianna; Eterovic, Agda Karina; Wulf, Gerburg M.; Cantley, Lewis C.; Mills, Gordon B.; Doyle, L. Austin; Winer, Eric; Hortobagyi, Gabriel N.; Gonzalez-Angulo, Ana Maria; Meric-Bernstam, Funda 分享 收藏 The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, enhances antitumor efficacy of paclitaxel and Nab-paclitaxel in TP53 wild-type MCF-7 breast cancer modelsPairawan, S. S.; Yuca, E.; Evans, K.; Annis, A.; Narasimhan, N.; Sutton, D.; Carvajal, L. A.; Ren, J-G; Santiago, S.; Guerlavais, V.; Akcakanat, A.; Tapia, C.; Dumbrava, E. E. Illeana; Aivado, M.; Meric-Bernstam, F. 分享 收藏 分享 收藏 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
